PTC Therapeutics Inc (NAS:PTCT)
$ 36.53 3.23 (9.7%) Market Cap: 2.80 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

PTC Therapeutics Inc APHENITY Topline Results Call Transcript

May 17, 2023 / 12:00PM GMT
Release Date Price: $58.29 (+7.55%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the APHENITY Top Line Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I will now hand the conference over to your speaker host, Dr. Matthew Klein. Please go ahead.

Matthew B. Klein
PTC Therapeutics, Inc. - CEO & Director

Thank you all for joining this morning's call. We are excited to share the positive Top Line results of APHENITY, the Phase III trial of Sepiapterin in patients with phenylketonuria.

Before I begin, I refer you to our forward-looking statements on this slide, which are also posted on our website as well as our Risk Factors section in our most recent 10-K. We are thrilled to announce that we met the primary endpoint of blood phenylalanine reduction in the APHENITY study with highly statistically significant and clinically meaningful results.

Sepiapterin demonstrated substantial Phe reduction of 63% in the overall primary analysis population and 69% in the subset of classical PKU patients. The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot